Korea United Pharm Inc. (033270.KS)
KRW 18480.0
(-1.75%)
KRW 18480.0
(-1.75%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 468.86 Billion KRW | 12.2% |
| 2022 | 417.89 Billion KRW | 9.96% |
| 2021 | 380.03 Billion KRW | 7.53% |
| 2020 | 353.43 Billion KRW | 6.7% |
| 2019 | 331.24 Billion KRW | 9.7% |
| 2018 | 301.95 Billion KRW | 13.6% |
| 2017 | 265.79 Billion KRW | 13.48% |
| 2016 | 234.22 Billion KRW | 1.61% |
| 2015 | 230.5 Billion KRW | 6.18% |
| 2014 | 217.1 Billion KRW | 12.17% |
| 2013 | 193.53 Billion KRW | 3.18% |
| 2012 | 187.57 Billion KRW | 10.28% |
| 2011 | 170.08 Billion KRW | 25.01% |
| 2010 | 136.05 Billion KRW | 11.06% |
| 2009 | 122.5 Billion KRW | 39.33% |
| 2008 | 87.92 Billion KRW | 14.15% |
| 2007 | 77.02 Billion KRW | 9.08% |
| 2006 | 70.61 Billion KRW | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 486.8 Billion KRW | 3.83% |
| 2024 Q2 | 486.02 Billion KRW | -0.16% |
| 2023 Q4 | 468.86 Billion KRW | -0.44% |
| 2023 Q2 | 452.73 Billion KRW | 2.91% |
| 2023 FY | 468.86 Billion KRW | 12.2% |
| 2023 Q1 | 439.91 Billion KRW | 5.27% |
| 2023 Q3 | 470.91 Billion KRW | 4.02% |
| 2022 Q3 | 427.91 Billion KRW | 4.94% |
| 2022 Q1 | 397.48 Billion KRW | 4.59% |
| 2022 FY | 417.89 Billion KRW | 9.96% |
| 2022 Q2 | 407.78 Billion KRW | 2.59% |
| 2022 Q4 | 417.89 Billion KRW | -2.34% |
| 2021 Q4 | 380.03 Billion KRW | 1.51% |
| 2021 FY | 380.03 Billion KRW | 7.53% |
| 2021 Q1 | 366.4 Billion KRW | 3.67% |
| 2021 Q2 | 365.73 Billion KRW | -0.19% |
| 2021 Q3 | 374.36 Billion KRW | 2.36% |
| 2020 FY | 353.43 Billion KRW | 6.7% |
| 2020 Q1 | 345.61 Billion KRW | 4.34% |
| 2020 Q3 | 350.32 Billion KRW | 1.76% |
| 2020 Q4 | 353.43 Billion KRW | 0.89% |
| 2020 Q2 | 344.24 Billion KRW | -0.4% |
| 2019 Q4 | 331.24 Billion KRW | 2.84% |
| 2019 FY | 331.24 Billion KRW | 9.7% |
| 2019 Q1 | 313.39 Billion KRW | 3.79% |
| 2019 Q2 | 311.45 Billion KRW | -0.62% |
| 2019 Q3 | 322.09 Billion KRW | 3.42% |
| 2018 Q3 | 291.38 Billion KRW | 2.82% |
| 2018 Q1 | 275.58 Billion KRW | 3.68% |
| 2018 Q2 | 283.4 Billion KRW | 2.84% |
| 2018 FY | 301.95 Billion KRW | 13.6% |
| 2018 Q4 | 301.95 Billion KRW | 3.63% |
| 2017 Q1 | 238.34 Billion KRW | 1.76% |
| 2017 Q4 | 265.79 Billion KRW | 6.22% |
| 2017 Q3 | 250.23 Billion KRW | 4.94% |
| 2017 Q2 | 238.46 Billion KRW | 0.05% |
| 2017 FY | 265.79 Billion KRW | 13.48% |
| 2016 Q1 | 240.83 Billion KRW | 0.0% |
| 2016 Q4 | 234.22 Billion KRW | -1.99% |
| 2016 Q3 | 238.97 Billion KRW | 1.02% |
| 2016 Q2 | 236.56 Billion KRW | -1.77% |
| 2016 FY | 234.22 Billion KRW | 1.61% |
| 2015 Q2 | 217.49 Billion KRW | -0.91% |
| 2015 Q1 | 219.49 Billion KRW | 1.1% |
| 2015 Q3 | 223.9 Billion KRW | 2.94% |
| 2015 FY | 230.5 Billion KRW | 6.18% |
| 2014 Q1 | 205.69 Billion KRW | 6.28% |
| 2014 Q2 | 208.28 Billion KRW | 1.26% |
| 2014 FY | 217.1 Billion KRW | 12.17% |
| 2014 Q4 | 217.1 Billion KRW | 0.99% |
| 2014 Q3 | 214.96 Billion KRW | 3.21% |
| 2013 FY | 193.53 Billion KRW | 3.18% |
| 2013 Q2 | 198.1 Billion KRW | 2.39% |
| 2013 Q1 | 193.47 Billion KRW | 3.14% |
| 2013 Q4 | 193.53 Billion KRW | 1.02% |
| 2013 Q3 | 191.58 Billion KRW | -3.29% |
| 2012 Q4 | 187.57 Billion KRW | 0.0% |
| 2012 FY | 187.57 Billion KRW | 10.28% |
| 2012 Q1 | 170.28 Billion KRW | 0.0% |
| 2011 Q1 | 154.91 Billion KRW | 13.87% |
| 2011 Q2 | 159.51 Billion KRW | 2.97% |
| 2011 Q3 | 165.32 Billion KRW | 3.64% |
| 2011 FY | 170.08 Billion KRW | 25.01% |
| 2010 Q4 | 136.05 Billion KRW | 4.35% |
| 2010 Q1 | 123.67 Billion KRW | 0.96% |
| 2010 FY | 136.05 Billion KRW | 11.06% |
| 2010 Q2 | 127.34 Billion KRW | 2.97% |
| 2010 Q3 | 130.37 Billion KRW | 2.38% |
| 2009 Q3 | 108.31 Billion KRW | 1.67% |
| 2009 Q4 | 122.5 Billion KRW | 13.1% |
| 2009 Q2 | 106.53 Billion KRW | 9.24% |
| 2009 Q1 | 97.51 Billion KRW | 10.91% |
| 2009 FY | 122.5 Billion KRW | 39.33% |
| 2008 Q2 | 85.76 Billion KRW | 2.52% |
| 2008 Q3 | 89.16 Billion KRW | 3.96% |
| 2008 Q1 | 83.66 Billion KRW | 0.0% |
| 2008 FY | 87.92 Billion KRW | 14.15% |
| 2008 Q4 | 87.92 Billion KRW | -1.39% |
| 2007 Q2 | 76.5 Billion KRW | 0.0% |
| 2007 Q3 | 77.49 Billion KRW | 1.3% |
| 2007 FY | 77.02 Billion KRW | 9.08% |
| 2006 FY | 70.61 Billion KRW | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -136.543% |
| Dong-A Socio Holdings Co., Ltd. | 1957.1 Billion KRW | 76.043% |
| Ildong Holdings Co., Ltd. | 876.99 Billion KRW | 46.538% |
| HANDOK Inc. | 790.33 Billion KRW | 40.676% |
| Kukje Pharma Co., Ltd. | 170.61 Billion KRW | -174.798% |
| Yuhan Corporation | 2814.07 Billion KRW | 83.339% |
| Dong-A ST Co., Ltd. | 1315.21 Billion KRW | 64.351% |
| SAMSUNG PHARM. Co., LTD. | 93.47 Billion KRW | -401.567% |
| Hanmi Pharm. Co., Ltd. | 1952.03 Billion KRW | 75.981% |
| Hanall Biopharma Co.,Ltd | 239.74 Billion KRW | -95.565% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | 0.009% |
| Dong Sung Bio Pharm.Co.,Ltd. | 114.97 Billion KRW | -307.799% |
| MYUNGMOON Pharm co.,Ltd | 236.54 Billion KRW | -98.209% |
| Hana Pharm Co., Ltd. | 348.38 Billion KRW | -34.581% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -136.543% |
| Ilsung Pharmaceuticals Co., Ltd. | 419.18 Billion KRW | -11.849% |
| REYON Pharmaceutical Co., Ltd. | 499.77 Billion KRW | 6.186% |
| Aprogen pharmaceuticals,Inc. | 589.39 Billion KRW | 20.451% |
| JW Holdings Corporation | 1176.26 Billion KRW | 60.14% |
| Ildong Pharmaceutical Co., Ltd. | 611.26 Billion KRW | 23.296% |
| Chong Kun Dang Pharmaceutical Corp. | 1402.42 Billion KRW | 66.568% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 27.313% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | -33.928% |
| Hyundai Pharmaceutical Co., Ltd. | 154.04 Billion KRW | -204.374% |
| Samil Pharmaceutical Co.,Ltd | 370.68 Billion KRW | -26.487% |
| Jeil Pharmaceutical Co.,Ltd | 487.32 Billion KRW | 3.789% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -136.543% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1078.06 Billion KRW | 56.509% |
| Daewoong pharmaceutical Co.,Ltd | 1770.31 Billion KRW | 73.515% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 27.313% |
| Yuhan Corporation | 2814.07 Billion KRW | 83.339% |
| Jeil Pharma Holdings Inc | 879.99 Billion KRW | 46.72% |
| Yungjin Pharm. Co., Ltd. | 226.6 Billion KRW | -106.91% |
| Suheung Co., Ltd. | 993.73 Billion KRW | 52.818% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 27.313% |
| Samjin Pharmaceuticals Co., Ltd. | 419.9 Billion KRW | -11.66% |
| CKD Bio Corp. | 293.78 Billion KRW | -59.593% |
| Daewon Pharmaceutical Co., Ltd. | 507.99 Billion KRW | 7.704% |
| Dongwha Pharm.Co.,Ltd | 564.97 Billion KRW | 17.012% |
| Whan In Pharm Co.,Ltd. | 401.22 Billion KRW | -16.857% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | -33.928% |
| Chong Kun Dang Holdings Corp. | 1456 Billion KRW | 67.798% |
| Boryung Corporation | 922.36 Billion KRW | 49.167% |
| Bukwang Pharmaceutical Co., Ltd. | 442.46 Billion KRW | -5.966% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | 0.009% |
| JW Lifescience Corporation | 255.83 Billion KRW | -83.266% |